Mereo BioPharma Group plc (MREO)

Mereo BioPharma Group Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	-	10	-	49.37	-
Cost of Revenue	-	2.57	-1.15	24.25	-
Gross Profit	-	7.43	1.15	25.13	-
Selling, General & Admin	26.43	18.42	26.11	21.57	28.97
Research & Development	19.28	16.14	27.74	31.9	22.32
Operating Expenses	45.72	34.56	53.84	53.47	51.29
Operating Income	-45.72	-27.14	-52.7	-28.35	-51.29
Interest Expense	-1.37	-2.88	-4.18	-5.11	-8.5
Interest & Investment Income	3.04	2.13	0.84	0	0.01
Currency Exchange Gain (Loss)	1.21	-2.35	2.72	-1.29	-2.49
Other Non Operating Income (Expenses)	-0.42	0.24	10.37	53.88	-150.19
EBT Excluding Unusual Items	-43.25	-30	-42.94	19.13	-212.46
Gain (Loss) on Sale of Investments	-	-	-	-	0.05
Gain (Loss) on Sale of Assets	-	-	-	0.15	-14.84
Pretax Income	-43.25	-30	-42.94	19.28	-227.25
Income Tax Expense	-	-0.53	-0.72	2.05	-3.85
Net Income	-43.25	-29.47	-42.22	17.23	-223.4
Net Income to Common	-43.25	-29.47	-42.22	17.23	-223.4
Shares Outstanding (Basic)	148	132	121	106	68
Shares Outstanding (Diluted)	148	132	121	111	68
Shares Change (YoY)	12.16%	9.33%	8.63%	63.82%	279.04%
EPS (Basic)	-0.29	-0.22	-0.35	0.16	-3.30
EPS (Diluted)	-0.29	-0.22	-0.35	-0.31	-3.30
Free Cash Flow	-32.83	-21.13	-48.83	-7.82	-38.72
Free Cash Flow Per Share	-0.22	-0.16	-0.41	-0.07	-0.57
Gross Margin	-	74.26%	-	50.89%	-
Operating Margin	-	-271.36%	-	-57.42%	-
Profit Margin	-	-294.66%	-	34.90%	-
Free Cash Flow Margin	-	-211.32%	-	-15.83%	-
EBITDA	-45.13	-26.57	-52.52	-28.25	-49.11
EBITDA Margin	-	-265.70%	-	-57.22%	-
D&A For EBITDA	0.58	0.57	0.18	0.1	2.18
EBIT	-45.72	-27.14	-52.7	-28.35	-51.29
EBIT Margin	-	-271.36%	-	-57.42%	-
Effective Tax Rate	-	-	-	10.64%	-

Updated Mar 26, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q